These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

398 related items for PubMed ID: 15693004

  • 1. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study.
    Gerloni V, Pontikaki I, Gattinara M, Desiati F, Lupi E, Lurati A, Salmaso A, Fantini F.
    Arthritis Rheum; 2005 Feb; 52(2):548-53. PubMed ID: 15693004
    [Abstract] [Full Text] [Related]

  • 2. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
    Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M.
    Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087
    [Abstract] [Full Text] [Related]

  • 3. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.
    Ruperto N, Lovell DJ, Cuttica R, Wilkinson N, Woo P, Espada G, Wouters C, Silverman ED, Balogh Z, Henrickson M, Apaz MT, Baildam E, Fasth A, Gerloni V, Lahdenne P, Prieur AM, Ravelli A, Saurenmann RK, Gamir ML, Wulffraat N, Marodi L, Petty RE, Joos R, Zulian F, McCurdy D, Myones BL, Nagy K, Reuman P, Szer I, Travers S, Beutler A, Keenan G, Clark J, Visvanathan S, Fasanmade A, Raychaudhuri A, Mendelsohn A, Martini A, Giannini EH, Paediatric Rheumatology International Trials Organisation, Pediatric Rheumatology Collaborative Study Group.
    Arthritis Rheum; 2007 Sep; 56(9):3096-106. PubMed ID: 17763439
    [Abstract] [Full Text] [Related]

  • 4. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
    Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P.
    J Rheumatol; 2000 Apr; 27(4):841-50. PubMed ID: 10782805
    [Abstract] [Full Text] [Related]

  • 5. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.
    Shergy WJ, Isern RA, Cooley DA, Harshbarger JL, Huffstutter JE, Hughes GM, Spencer-Smith EA, Goldman AL, Roth SH, Toder JS, Warner D, Quinn A, Keenan GF, Schaible TF, PROMPT Study Group. Profiling Remicade Onset with MTX in a Prospective Trial.
    J Rheumatol; 2002 Apr; 29(4):667-77. PubMed ID: 11950005
    [Abstract] [Full Text] [Related]

  • 6. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
    Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, Brown C, Fraser A, Jarret S, Emery P.
    Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
    [Abstract] [Full Text] [Related]

  • 7. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial.
    Tynjälä P, Vähäsalo P, Tarkiainen M, Kröger L, Aalto K, Malin M, Putto-Laurila A, Honkanen V, Lahdenne P.
    Ann Rheum Dis; 2011 Sep; 70(9):1605-12. PubMed ID: 21623000
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
    Higashida J, Wun T, Schmidt S, Naguwa SM, Tuscano JM.
    J Rheumatol; 2005 Nov; 32(11):2109-15. PubMed ID: 16265687
    [Abstract] [Full Text] [Related]

  • 10. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate.
    Alsufyani K, Ortiz-Alvarez O, Cabral DA, Tucker LB, Petty RE, Malleson PN.
    J Rheumatol; 2004 Jan; 31(1):179-82. PubMed ID: 14705239
    [Abstract] [Full Text] [Related]

  • 11. Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis.
    Woo P, Southwood TR, Prieur AM, Doré CJ, Grainger J, David J, Ryder C, Hasson N, Hall A, Lemelle I.
    Arthritis Rheum; 2000 Aug; 43(8):1849-57. PubMed ID: 10943876
    [Abstract] [Full Text] [Related]

  • 12. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years.
    Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Sieper J.
    Rheumatology (Oxford); 2005 May; 44(5):670-6. PubMed ID: 15757965
    [Abstract] [Full Text] [Related]

  • 13. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials.
    Doyle MK, Rahman MU, Han C, Han J, Giles J, Bingham CO, Bathon J.
    Semin Arthritis Rheum; 2009 Oct; 39(2):123-31. PubMed ID: 18823645
    [Abstract] [Full Text] [Related]

  • 14. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents.
    Lurati A, Pontikaki I, Teruzzi B, Desiati F, Gerloni V, Gattinara M, Cimaz R, Fantini F.
    Arthritis Rheum; 2006 May; 54(5):1602-7. PubMed ID: 16646003
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis.
    Horneff G, Ebert A, Fitter S, Minden K, Foeldvari I, Kümmerle-Deschner J, Thon A, Girschick HJ, Weller F, Huppertz HI.
    Rheumatology (Oxford); 2009 Aug; 48(8):916-9. PubMed ID: 19483091
    [Abstract] [Full Text] [Related]

  • 16. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis.
    Silverman E, Spiegel L, Hawkins D, Petty R, Goldsmith D, Schanberg L, Duffy C, Howard P, Strand V.
    Arthritis Rheum; 2005 Feb; 52(2):554-62. PubMed ID: 15693001
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
    Gerloni V, Pontikaki I, Gattinara M, Fantini F.
    Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
    [Abstract] [Full Text] [Related]

  • 19. Subcutaneous administration of polymerized-type I collagen for the treatment of patients with rheumatoid arthritis. An open-label pilot trial.
    Furuzawa-Carballeda J, Cabral AR, Zapata-Zuñiga M, Alcocer-Varela J.
    J Rheumatol; 2003 Feb; 30(2):256-9. PubMed ID: 12563677
    [Abstract] [Full Text] [Related]

  • 20. Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS).
    Mariette X, Ravaud P, Steinfeld S, Baron G, Goetz J, Hachulla E, Combe B, Puéchal X, Pennec Y, Sauvezie B, Perdriger A, Hayem G, Janin A, Sibilia J.
    Arthritis Rheum; 2004 Apr; 50(4):1270-6. PubMed ID: 15077311
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.